SoCal TBA online Event: Opportunities and Challenges as a Neuroscientist

*本活動將以中文進行，歡迎各領域的朋友一起參與

隨著合成生物學以及基因編輯技術的演進，以及人工智慧的興起，神經科學正在廣納跨領域的知識而呈現嶄新的樣貌，近年來在基礎研究的各種進展，是否也讓各種神經疾病的治療帶來新的契機?

SoCal TBA 本次榮幸邀請到在Eli Lilly Neuroscience NGTx 擔任Director and Project Lead的黃正球博士(Cheng-Chiu Joe Huang) 主講。黃博士擁有豐富的學術研究經歷，其成果曾刊登於著名期刊(Nature Medicine, Neuron等)，以及具有開發神經退化性疾病和疼痛管理藥物的經驗。本次活動中他將分享自身在產學界的歷程，也會與我們一同探討神經科學在生醫製藥的展望。你不會想錯過:

• 他是如何踏上神經科學之途
• 學界 vs. 業界的職涯抉擇
• 博士後研究經歷對進入業界重要嗎?
• 哪些神經科學的新知與里程碑，以及跨領域的知識，將帶來新的產業革命
• 業界如何學習過去的經驗，將神經疾病治療帶向新的道路

Agenda:

11:00 AM - 11:45 AM: Speaker Talk

11:45 AM - 12:00 PM: Q&A

Follow us: https://www.facebook.com/SoCalTBA

Subscribe to SoCal TBA newsletter: https://tinyurl.com/socaltba

The meeting link will be sent before the meeting after registration.

Speaker: 黃正球 (Cheng-Chiu Joe Huang), Director and Project Lead of Neuroscience NGTx at Eli Lilly

Speaker LinkedIn: https://www.linkedin.com/in/cheng-chiu-joe-huang-9765253a/

Moderator:

• 劉政昕 (Cheng-Hsin Adam Liu), https://www.linkedin.com/in/adam-cheng-hsin-liu
• 游若嫺 (Jo-Hsien Yu): https://www.linkedin.com/in/jo-hsien-yu/

Speaker Bio

Dr. Cheng-Chiu (Joe) Huang, a Ph.D. in Developmental Biology and Neuroscience, has extensive experience working on preclinical animal models, in vivo pharmacology, early clinical development, and project management in both academia and the biotech industry.

His track record of innovations in genetic medicine (RNA and Gene Therapy) for neurological and immunological diseases includes not only his publications about genetic and viral tools development for sensory disorders, but also multiple discovery programs in neuro-immune interactions, autonomic hyperreflexia, and immuno-oncology. After transitioning into industry, he has also managed a pipeline project in postsurgical pain management toward Investigational New Drug Application (IND) application and successful clinical development.

Dr. Huang has also established his management and leadership roles across different stages in his career. Supervising junior scientists in academia, he served as the director of cross-functional teams, with external partners and CROs on harnessing novel therapeutic modalities to tackle chronic pain and neurodegenerative diseases, and on building IP moat around the assets. He has been a senior scientific prospector of more than 30 due diligence activities in scouting assets and M&A targets ranging from preclinical to human phase 2 stages, and is currently the Director and Project Lead of Neuroscience NGTx at Eli Lilly.